Loading
HER2 Mutant Non Small Cell Lung Cancer / Trastuzumab deruxtecan · Phase 2 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 single-arm study of trastuzumab deruxtecan in HER2-mutant metastatic non-squamous NSCLC, currently enrolling or recently completed enrollment (n=72). No efficacy or safety results are posted in this registry record; the study is in active follow-up with final analysis planned up to 28 months from enrollment.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. HER2-mutant Non-Small Cell Lung Cancer; age from 18 Years. Intervention: T-DXd arm. n = 72. 28 sites: China.
This is a registered Phase 2 single-arm study of trastuzumab deruxtecan in HER2-mutant metastatic non-squamous NSCLC, currently enrolling or recently completed enrollment (n=72). No efficacy or safety results are posted in this registry record; the study is in active follow-up with final analysis planned up to 28 months from enrollment.
This is a registry record with no posted results; efficacy and safety data are not yet reported.
Clinicians should recognize this as an active trial evaluating a novel targeted therapy in a molecularly defined NSCLC population. No evidence of efficacy or safety is available from this registry record; results must await publication of the final analysis.
This is a clinical trial registry record describing a planned or active Phase 2 single-arm study with no results posted; it documents design and enrollment only.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as an active trial evaluating a novel targeted therapy in a molecularly defined NSCLC population. No evidence of efficacy or safety is available from this registry record; results must await publication of the final analysis.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05246514). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 72 participants (ACTUAL). Conditions: HER2-mutant Non-Small Cell Lung Cancer. Interventions: DRUG: Trastuzumab deruxtecan. Primary outcome measures: ICR-assessed ORR (Objective Response Rate) , Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off). Brief summary: The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.